Literature DB >> 28051324

Progress Toward Achieving the UNAIDS 90-90-90 Goals in HIV Care From Diagnosis to Durable Viral Suppression in the Country of Georgia.

Nikoloz Chkhartishvili1, Otar Chokoshvili1, Akaki Abutidze1, Natia Dvali1, Carlos Del Rio2, Tengiz Tsertsvadze1,3.   

Abstract

Successful engagement in HIV care is required to reach UNAIDS targets of 90-90-90. We analyzed routine programmatic data to quantify losses along the HIV care continuum in the country of Georgia. Analysis was limited to diagnosed persons and did not include estimated number of HIV-infected persons. Cascade of HIV care continuum was constructed for adult (age ≥18 years) HIV-infected persons newly diagnosed in Georgia in 2008-2012. Data were extracted from the national AIDS Health Information System as of June 30, 2014. Among 1,931 patients included, the median age was 37 years, 72% were men, and 40.7% had CD4 count <200 cells/mm3. A total of 1,711 (88.6%) were linked to care, 1,333 (69.0%) ever started antiretroviral therapy (ART), 1,044 (54.1%) ever achieved viral suppression, and 792 (41.0%) maintained viral suppression till the end of follow-up. Overall, 1,139 patients were lost from HIV diagnosis to maintaining viral suppression, including 761 (66.8%) patients who remained alive and 378 (33.2%) patients who died. Among 378 deceased patients, 324 (85.7%) died before achieving viral suppression after the median 3.5 months since diagnosis and 54 (14.3%) died after achieving viral suppression after the median 21.2 months since diagnosis. Among 761 alive patients without viral suppression, 297 (39.0%) were fully disengaged, 144 (18.9%) had never been prescribed ART, 161 (21.2) either never achieved suppression or discontinued ART, and 159 (20.9%) experienced rebound while on ART. Efforts are needed to improve earlier HIV diagnosis, to reduce the number of patients not in care, and to extend durability of viral suppression.

Entities:  

Keywords:  HIV; antiretroviral therapy; epidemiology

Mesh:

Substances:

Year:  2017        PMID: 28051324      PMCID: PMC5650711          DOI: 10.1089/AID.2016.0103

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  12 in total

1.  Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA.

Authors:  Gary Marks; Nicole Crepaz; Robert S Janssen
Journal:  AIDS       Date:  2006-06-26       Impact factor: 4.177

2.  High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa.

Authors:  Frank Tanser; Till Bärnighausen; Erofili Grapsa; Jaffer Zaidi; Marie-Louise Newell
Journal:  Science       Date:  2013-02-22       Impact factor: 47.728

3.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

Review 4.  The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection.

Authors:  Edward M Gardner; Margaret P McLees; John F Steiner; Carlos Del Rio; William J Burman
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

5.  Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals.

Authors:  Ard I van Sighem; Luuk A J Gras; Peter Reiss; Kees Brinkman; Frank de Wolf
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

6.  Human immunodeficiency virus transmission at each step of the care continuum in the United States.

Authors:  Jacek Skarbinski; Eli Rosenberg; Gabriela Paz-Bailey; H Irene Hall; Charles E Rose; Abigail H Viall; Jennifer L Fagan; Amy Lansky; Jonathan H Mermin
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

7.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

8.  The cascade of care in the Eastern European country of Georgia.

Authors:  N Chkhartishvili; L Sharavdze; O Chokoshvili; J A DeHovitz; C del Rio; T Tsertsvadze
Journal:  HIV Med       Date:  2014-06-12       Impact factor: 3.180

9.  Continuous Retention and Viral Suppression Provide Further Insights Into the HIV Care Continuum Compared to the Cross-sectional HIV Care Cascade.

Authors:  Jonathan Colasanti; Jane Kelly; Eugene Pennisi; Yi-Juan Hu; Christin Root; Denise Hughes; Carlos Del Rio; Wendy S Armstrong
Journal:  Clin Infect Dis       Date:  2015-11-12       Impact factor: 9.079

10.  Risk factors for loss to follow-up prior to ART initiation among patients enrolling in HIV care with CD4+ cell count ≥200 cells/μL in the multi-country MTCT-Plus Initiative.

Authors:  R Charon Gwynn; Ashraf Fawzy; Ida Viho; Yingfeng Wu; Elaine J Abrams; Denis Nash
Journal:  BMC Health Serv Res       Date:  2015-06-25       Impact factor: 2.655

View more
  1 in total

1.  The Impact of a Fogarty International Center-Supported Tuberculosis Research Training Program in the Country of Georgia.

Authors:  Russell R Kempker; Nestani Tukvadze; Lisa Sthreshley; Lisa Sharling; Dawn L Comeau; Matthew J Magee; Carlos Del Rio; Zaza Avaliani; Henry M Blumberg
Journal:  Am J Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.